Author

Sebastian Akle Serrano

Alnylam Pharmaceuticals (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 1 Organism:human· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Aaron M. HollemaniD· 1 shared Aimée M. DeatoniD· 1 shared Anna Borodovsky· 1 shared Lucas D. WardiD· 1 shared Lynne KrohniD· 1 shared Mollie E. Plekan· 1 shared Paul NioiiD· 1 shared Philip J. LoGerfo· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Aaron M. HollemanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Rare predicted loss-of-function and damaging missense variants in CFHR5 associate with protection from age-related macular degeneration

Aaron M. Holleman, Aimée M. Deaton, Rachel A. Hoffing, Lynne Krohn, Philip J. LoGerfo, Paul Nioi, Mollie E. Plekan, Sebastian Akle Serrano, Simina Ticau, Tony E. Walshe, Anna Borodovsky, Lucas D. Ward

The paper identifies rare variants in CFHR5 associated with reduced risk of AMD and increased retinal thickness, suggesting CFHR5 as a therapeutic target.

medRxiv · Nov 13, 2024 · PreprintGenetic & Genomic Medicine